Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3382663 | Personalized Medicine Universe | 2012 | 8 Pages |
Abstract
DC vaccine-based immunotherapy demonstrates promising OS times and tolerable toxicities in the setting of breast carcinoma. A full risk/benefit analysis of DC-based vaccines in patients with metastatic breast carcinoma will be determined in a future phase II trial.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Shinichiro Akiyama, Ariko Yamauchi, Teruyo Yamashita, Hiroshi Nimura, Hiroyuki Abe,